CINC424A2X01B Rollover Protocol (NCT02386800)
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies
🩺 Plain-English Summary (8th-Grade Level)
This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.
Who can join: Review the eligibility criteria below.
Location: Novartis Investigative Site — Darlinghurst, New South Wales
Age range: 1 Month to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (97 Sites)
Showing the first 25 of 97 sites.
- Novartis Investigative Site — Darlinghurst, New South Wales
- Novartis Investigative Site — Herston, Queensland
- Novartis Investigative Site — Wooloongabba, Queensland
- Novartis Investigative Site — Bedford Park, South Australia
- Novartis Investigative Site — Box Hill, Victoria
- Novartis Investigative Site — Clayton, Victoria
- Novartis Investigative Site — Franston, Victoria
- Novartis Investigative Site — Perth, Western Australia
- Novartis Investigative Site — St Leonards,
- Novartis Investigative Site — Leuven, Vlaams Brabant
- Novartis Investigative Site — Antwerp,
- Novartis Investigative Site — Bruges,
- Novartis Investigative Site — Liège,
- Novartis Investigative Site — Pleven,
- Novartis Investigative Site — Plovdiv,
- Novartis Investigative Site — Sofia,
- Novartis Investigative Site — Toronto, Ontario
- Novartis Investigative Site — Santiago, RM
- Novartis Investigative Site — Viña del Mar, Valparaiso
- Novartis Investigative Site — Santiago,
- Novartis Investigative Site — Hangzhou, Zhejiang
- Novartis Investigative Site — Beijing,
- Novartis Investigative Site — Paris,
- Novartis Investigative Site — Dresden, Saxony
- Novartis Investigative Site — Jena, Thuringia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Myelofibrosis
- P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk — Los Angeles, California
- Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis — Seattle, Washington
- Study of Canakinumab in Patients With Myelofibrosis — Los Angeles, California
- Decitabine in Treating Patients With Myelofibrosis — Chicago, Illinois
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Birmingham, Alabama
Explore by condition: All Primary Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.